Paul LePage: OPIOID PRESCRIBING

Gifts and Perks to Doctors

In 2017, LePage Refused to Sign a Bipartisan Law Cutting Back Gifts, Speaking Fees, And Food From Pharmaceutical Companies To Doctors, Especially Those Prescribing Opioids. In June 2017, LD 911 became law without Governor LePage’s signature after passing both chambers of the Legislature without a roll call vote. “A bill that would curtail gifts, speaking and consulting fees and expensive food flowing from pharmaceutical companies to doctors has passed the Legislature and awaits the signature of Gov. Paul LePage. Rep. Scott Hamann, D-South Portland, said the goal of the bill is to ensure doctors do not have conflicting interests when prescribing drugs – especially opioids – since Maine is in the midst of an opioid crisis.” [Maine State Legislature, LD 911, 6/28/17; Portland Press Herald, 6/20/17]

  • HEADLINE: “Legislature Passes Bill To Rein In Drug Company Perks For Doctors.” [Portland Press Herald, 6/20/17]
  • The Legislation Banned All Cash Gifts From Pharmaceutical Companies To Doctors And Only Allowed Non-Cash Gifts Of “Minimal” Value. “Hamann’s bill would ban all cash gifts and only allow noncash gifts of ‘minimal’ value. Any gifts where ‘reciprocity is expected or implied’ would also be prohibited.” [Portland Press Herald, 6/20/17]
  • Portland Press Herald: “Rep. Scott Hamann, D-South Portland, Said The Goal Of The Bill Is To Ensure Doctors Do Not Have Conflicting Interests When Prescribing Drugs – Especially Opioids – Since Maine Is In The Midst Of An Opioid Crisis.” On June 28, 2017, LD 911 became law without Governor LePage’s signature after passing both chambers of the Legislature without a roll call vote. “A bill that would curtail gifts, speaking and consulting fees and expensive food flowing from pharmaceutical companies to doctors has passed the Legislature and awaits the signature of Gov. Paul LePage. Rep. Scott Hamann, D-South Portland, said the goal of the bill is to ensure doctors do not have

conflicting interests when prescribing drugs – especially opioids – since Maine is in the midst of an opioid crisis.” [Portland Press Herald, 6/20/17]

  • Maine Medical Association Vice President Gordon Smith On The Bill: “It Would Eliminate Any Perception That There’s A Conflict Of Interest Among Doctors. The Bill Is Also Consistent With Our Code Of Ethics.” “The Maine Medical Association, which represents doctors’ interests before the Legislature, was officially neutral on the bill. But Gordon Smith, the association’s executive vice president, said he sees some benefits to it. ‘It would eliminate any perception that there’s a conflict of interest among doctors,’ Smith said. ‘The bill is also consistent with our code of ethics.’” [Portland Press Herald, 6/20/17]
  • Harvard Medical School’s Medical Ethics Expert Dr. Eric Campbell: “To Be Accepting Payments For Opioids In The Face Of The Opioid Epidemic In Many Ways Can Be Viewed As Professionally Irresponsible.” “‘This is pretty vexing,’ said Dr. Eric Campbell, a medical ethics expert at Harvard Medical School, speaking broadly about the practice. ‘To be accepting payments for opioids in the face of the opioid epidemic in many ways can be viewed as professionally irresponsible.’” [Portland Press Herald, 12/25/16]

HEADLINE: “Even Amid Crisis, Opioid Makers Plied Doctors With Perks.” [Portland Press Herald, 12/25/16]

Portland Press Herald: Between 2014 And 2015, Payments From Pharmaceutical Companies To Doctors Related To Opioids Doubled. “While the opioid crisis deepened in Maine over the past three years, drug companies selling opioids increasingly showed up on the doorsteps of physicians’ offices – offering free food and beverages, consulting or speaking fees, discount coupons for drugs and other freebies. The total payments to doctors related to opioids doubled from 2014 to 2015.” [Portland Press Herald, 12/25/16]

  • 2014-2015: Opioid Pharmaceutical Industry Spending Increased From $21,654 To $42,550 On Maine Doctors. “Overall, opioid industry spending on Maine doctors increased from $21,654 in 2014 to $42,550 in 2015.

Portland Press Herald: “While The Opioid Crisis Deepened In Maine Over The Past Three Years, Drug Companies Selling Opioids Increasingly Showed Up On The Doorsteps Of Physicians’ Offices – Offering Free Food And Beverages, Consulting Or Speaking Fees, Discount Coupons For Drugs And Other Freebies.” “While the opioid crisis deepened in Maine over the past three years, drug companies selling opioids increasingly showed up on the doorsteps of physicians’ offices – offering free food and beverages, consulting or speaking fees, discount coupons for drugs and other freebies. The total payments to doctors related to opioids doubled from 2014 to 2015.” [Portland Press Herald, 12/25/16]

2017-2018: Payments To Maine Doctors From Pharmaceutical Companies Dropped By $1.22 Million:

Image: see original report, p. 166

[Open Payments Data, CMS, accessed 9/16/19]

In 2017, LePage Refused to Sign Bipartisan Legislation That Required Opioid Prescribers to Develop an Opioid Medication Prescribing Policy That Included Informed Consent and Counseling on the Risk of Opioid Use. In June 2017, LePage allowed LD479 to become law without his signature after the bill passed both chambers without a roll call vote. LD479 “requires health care entities that include prescribers of opioid medications to develop an opioid medication prescribing policy that includes risk assessment, informed consent and counseling on the risk of opioid use. The policy must be developed by January 1, 2018.” [Summaries of Bills, LD479, 2017; Maine State Legislature, LD479, 2017]

July 2011: LePage Signed Bill That Repealed Requirement For Pharmaceutical To Disclose Actual And Best Prices For Drugs Dispensed In Maine. According to a brief released by Epstein, Becker, Green, “LD 719 further repeals Maine's actual price disclosure statute, § 2698-B, effective September 28, 2011. This statute requires prescription drug manufacturers to disclose, on a quarterly basis, the average manufacturer price ("AMP") and best price ("BP") for all drugs dispensed in Maine that are subject to the Medicaid Drug Rebate Program. Prescription drug manufacturers will no longer be required to submit these price reports to Maine, although federal reporting requirements[7] remain in effect.” [EBG Law, 8/15/11]

Prescription Drug Prices Sky-Rocketed Under Paul LePage

2014-2018: Maine Health Data Organization Said Mainers’ Spending On Prescription Drugs Increased By $400,000. According to the Maine Health Data Organization, “In 2014, the federal government estimated Mainers spent $1.5 billion on prescription drugs. In 2018, the Maine Health Data Organization estimated that had increased to almost $1.9 billion. After accounting for the cost of living and population changes, that’s the equivalent of a 19 percent increase in just four years. [Maine Center for Economic Policy, 4/16/19]

2012-2017: Under LePage, Drug Prices In Maine Increased By Almost 60 Percent While Annual Income For Mainers Over 50 Increased By Less Than 6 Percent. According to AARP, “The average annual cost of prescription drug treatment increased 57.8% between 2012 and 2017, while the annual income for Mainers only increased 5.6%.6.” [AARP, Accessed 4/27/21]

2012: LePage Sought To Cut Medicaid Prescription Drug Coverage. In 2012, PEW Research noted LePage sought massive cuts to Medicaid, saying, “Some of LePage's proposed Medicaid cuts, such as eliminating dental care, physical therapy and chiropractic services, are not too different from ones that governors in both parties are recommending in states across the country. Neither are his proposed reductions in payments to hospitals and doctors or limits on prescription drug coverage. But LePage also wants to get at enrollment, and this is what makes him, at the moment, the most draconian of the governors when it comes to health policy.” [PEW Research, 2/6/12]

2013: LePage Proposed State Budget That Cut Prescription Drug Payment Aid For Seniors. On January 11, 2013, the Bangor Daily News reported, “Gov. Paul LePage’s proposed budget for the next two years includes cuts that could be felt by rural hospitals, senior citizens who receive aid to help them pay for prescription drugs, and municipalities whose general assistance funds are in high demand.” [Bangor Daily News, 1/11/13]

  • LePage Sought Cuts To Medicare Savings Plan That Helped Seniors Pay For Prescription Drugs. “The two-year budget proposal also scales back the Medicare Savings Plan to the minimum levels mandated by the federal government. Currently, according to Mayhew, only Maine, Connecticut and Washington, D.C., exceed the federal minimum on that program, which offers senior citizens aid for prescription drugs through the state’s Medicaid program.” [Bangor Daily News, 1/11/13]

May 2018: LePage Allowed Bill To Authorize Study To Review Drug Prices, Increase Price Transparency To Pass Into Law Without His Signature. In May 2018, “he governor of Maine, Paul LePage, allowed legislation to pass into law without his signature that: (1) authorizes a study to review and overview drug prices and (2) has implications for top 25 drugs of different types.” [Policy & Medicine, 5/11/18]

Governor Janet Mills Immediately Signed Legislation To Increase Prescribing Transparency, Lower Drug Costs After Paul LePage Left Office

Foley Hoag LLP Drug Pricing Policy Watch: Mills Signed Into Law Prescription Drug Affordability Board That Appointed Members Tasked To “Lower Prescription Drug Costs.” According to a policy brief written by Foley Hoag LLP, in June 2019, Governor Janet Mills Signed into law the establishment of a Maine prescription drug affordability board that “according to advocates is designed to lower prescription drug costs in the state. The Board will consist of 5 members, with each member having expertise in either health care economics or clinical medicine. Two of the members will be appointed by the Senate President, two of the members will be appointed by the Speaker of the House and one member will be appointed by the Governor.” [JD Supra, 9/25/20]

June 2019: Mills Signed Bill Into Law That Created Drug Importation Program That Allowed Maine Medicaid Supplier To Import Cheaper Drugs From Canada, Other Countries. On June 24, 2019, AARP celebrated a bill signed by Governor Mills that allowed Maine to import drugs from Canada and other countries to create competition that would help lower prescription drug prices. [AARP, 6/24/19]

June 2019: Mills Signed Bill Into Law To Require Pharmacy Benefit Managers To “Pass Along To Consumers All Rebates They Receive From Drugmakers.” On June 24, 2019, AARP celebrated a bill signed by Governor Mills that required “pharmacy benefit managers (PBMs) to pass along to consumers all rebates they receive from drugmakers, and to direct PBMs to offer the cash price of a medicine to a consumer if it is lower than the patient's insurance copayment.” [AARP, 6/24/19]

June 2019: Mills Signed Bill Into Law That Required Pharmaceutical Manufacturers To Report Drug Price Increases Of More Than 20 Percent. On June 24, 2019, AARP celebrated a bill signed by Governor Mills that required “brand-name pharmaceutical manufacturers to annually report any price increases of more than 20 percent and for generic manufacturers to report 20 percent price hikes for medicines that cost at least $10 per pill or other unit.” [AARP, 6/24/19]

Source report (PDF)